STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for tough lymphomas
Disease control CompletedThis study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…
Matched conditions: STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a pill mop up hidden leukemia cells after chemo?
Disease control CompletedThis study tested the drug ibrutinib in 35 people with chronic lymphocytic leukemia (CLL) who still had small amounts of cancer cells after their first treatment. The goal was to see if ibrutinib could clear those leftover cells from the blood and bone marrow. Participants took i…
Matched conditions: STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Experimental combo shows promise for Tough-to-Treat leukemia
Disease control CompletedThis phase II trial tested a combination of two drugs—MOR00208 (an antibody that targets cancer cells) and lenalidomide (which boosts the immune system)—in 41 people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic leukemia (PLL). Some …
Matched conditions: STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC